Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to December 2013

Prostate Diagnostic and Assessment Tests

December 2013

By Michael Downey


Prostate cancer is the most common malignancy in US men (excluding non-melanoma skin cancer), afflicting one male in every six.46,47 A significant percentage of men have underlying prostate cancer without even knowing it.48-50

These men have access to an arsenal of tools for their doctors to diagnose and then monitor the success or failure of various treatment modalities, including “active surveillance” or “watchful waiting.”

As you’ve learned in this issue of Life Extension, one does not have to sit back and “watch” their PSA level steadily rise. Nutritional, hormonal, and drug approaches exist to help control early-stage, low-grade prostate tumors. There is data to support the efficacy of some of them as effective adjuvants in men with high-grade tumors as well.51-59

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.


  1. Available at: Accessed September 13, 2013.
  2. Strum SB, Pogliano D. A Primer on Prostate Cancer: An Empowered Patient’s Guide. Hollywood, FL: The Life Extension Foundation; 2005.
  3. D’Amico A, Chen M, Roehl K, Catalona W. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125-35.
  4. Available at:!ut/p/c1/hY1LDoIwFADP4gFMX1uosFUB-
    . Accessed September 13, 2013.
  5. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995 Oct;1(10):1089-94.
  6. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology. 1996 Apr;47(4):511-6.
  7. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997 Aug;50(2):239-43.
  8. Gion M, Mione R, Barioli P, et al. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem. 1998 Dec;44(12):2462-70.
    Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am. 1997 May;24(2):353-65.
  9. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009 May;6(5):255-61.
  10. Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011 Feb 1;301(1):1-6.
  11. Qin W, Smith C, Jensen M, Holick MF, Sauter ER. Vitamin d favorably alters the cancer promoting prostaglandin cascade. Anticancer Res. 2013 Sep;33(9):3861-6.
  12. van den Bemd GJ, Chang GT. Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets. 2002 Feb;3(1):85-94.
  13. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov;92(4):317-25.
  14. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005 Jun 15;65(12):5470-9.
  15. Available at:!ut/p/c1/hY1LDoIwFADP4gFMHwUrbFVAhRZq
    Accessed September 13, 2013.
  16. Sethi BK, Chanukya GV, Nagesh VS. Prolactin and cancer: Has the orphan finally found a home? Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S195-8.
  17. Available at:
    . Accessed September 13, 2013.
  18. Available at: Accessed September 13, 2013.
  19. Available at: Accessed September 13, 2013.
  20. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010 May;64(6):682-96.
  21. Miwa Y, Kaneda T, Yokoyama O. Correlation between the Aging Males’ Symptoms Scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med. 2006 Jul;3(4):723-6.
  22. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am. 2012 Jun;26(3):527-42,vii-viii.
  23. Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol. 2009 Feb;16(2):161-7.
  24. Kong HY, Byun J. Emerging roles of Human prostatic acid phosphatase. Biomol Ther (Seoul). 2013 Jan;21(1):10-20.
  25. Ligthart ST, Coumans FA, Bidard FC, et al. Circulating tumor cells count and morphological features in breast, colorectal and prostate cancer. PLoS One. 2013 Jun 27;8(6):e67148.
  26. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
  27. Available at: Accessed September 17, 2013.
  28. Available at: Accessed September 16, 2013.
  29. Fleischer AC. Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications. J Ultrasound Med. 2000 Jan;19(1):55-61.
  30. Available at:
    . Accessed September 16, 2013.
  31. Gupta RT, Kauffman CR, Polascik TJ, Taneja SS, Rosenkrantz AB. The state of prostate MRI in 2013. Oncology (Williston Park). 2013 Apr;27(4):262-70.
  32. Available at: Accessed September 16, 2013.
  33. Available at:
    . Accessed September 16, 2013.
  34. Tombal B, Lecouvet F. Modern detection of prostate cancer’s bone metastasis: Is the bone scan era over? Adv Urol. 2012;2012:893193.
  35. Available at: Accessed September 16, 2013.
  36. Tuck SP, Hanusch B, Walker J, Datta HK. Prostate cancer and osteoporosis. Curr Osteoporos Rep. 2013 Mar;11(1):11-20.
  37. Smith, M.R., McGovern, F.J., Fallon, M.A. et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001;91:2238–45.
  38. Bolotin HH Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic/osteoporotic interpretations and mislead assessment of antiresorptive therapy effectiveness. Bone. 2001;28:548–55.
  39. Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin. Rheumatol. 1999;18:364–8.
  40. von der Recke P, Hansen MA, Overgaard K. et al. The impact of degenerative conditions in the spine on bone mineral density and fracture risk prediction. Osteoporos Int. 1996;6:43–9.
  41. Available at: Accessed October 7, 2013.
  42. Harvei S. Epidemiology of prostatic cancer. Tidsskr Nor Laegeforen 1999 Oct 10;119(24):3589-94.
  43. Available at: Accessed September 16, 2013.
  44. Available at:
    . Accessed October 1, 2013.
  45. Available at: Accessed October 1, 2013.
  46. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10-29.
  47. Available at:
    . Accessed October 1, 2013.
  48. Harvei S. Epidemiology of prostatic cancer. Tidsskr Nor Laegeforen 1999 Oct 10;119(24):3589-94.
  49. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology. 1986 Oct;28(4):324-9.
  50. Sakr WA, Grignon DJ, Haas GP, et al. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract. 1995 Sep;191(9):838-41.
  51. Gallardo-Williams MT, Chapin RE, King PE, et al. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma(LNCaP) tumors in nude mice. Toxicol Pathol. 2004 Jan-Feb;32(1):73-8.
  52. Choi HY, Lim JE, Hong JH. Curcumin interrupts the interaction between the androgen receptor and Wnt/beta-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis. 2010 Dec;13(4):343-9.
  53. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47(4):293-303.
  54. Fleshner, N., Fair, W.R., Huryk, R. et al. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol. 1999;161:1651-4.
  55. Yang Y, Ikezoe T, Zheng Z, Taguchi H, Koeffler HP, Zhu WG. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol. 2007 Sep;31(3):593-600.
  56. McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, Rowland IR. Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol Nutr Food Res. 2008 May;52(5):567-80.
  57. von Holtz RL, Fink CS, Awad AB. Beta-Sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer. 1998;32(1):8-12.
  58. Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol. 2007 Oct;31(4):959-67.
  59. Thirugnanam S, Xu L, Ramaswamy K, Gnanasekar M. Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep. 2008 Dec;20(6):1387-92.